Broad Coalition Urges House of Representatives to Repeal Medical Device Tax
Wednesday, June 6, 2012
WASHINGTON, DC -- A broad coalition of medical
technology companies and leading associations wrote to Congressional
leaders today urging them to repeal the onerous medical device tax which
will destroy jobs and harm innovation. The letter had more than 700
signatories, including the Medical Device Manufacturers Association
(MDMA), the Advanced Medical Technology Association (AdvaMed), the
Medical Imaging & Technology Alliance (MITA), the U.S. Chamber of
Commerce, the National Association of Manufacturers (NAM), the National
Federation of Independent Business (NFIB), the National Venture Capital
Association and others.
"We continue to believe that
implementation of what was to be a $20 billion excise tax – and is now
estimated to collect over $30 billion in taxes – will adversely impact
patient care and innovation, and will substantially increase the costs
of health care,” the letter states.
The 2.3% medical device tax
was passed as a part of the health care reform legislation in 2010, and
the repeal bill is scheduled for a vote in the U.S. House of
Representatives this week.
The letter went on to note that, "At a
time when the federal government is working to promote investment in
U.S. industries of the future, it is inconsistent that a tax of this
magnitude would be considered on the medical device industry. We must
do all we can to encourage and promote research, development, investment
"Members of Congress are asking America’s innovators and
manufacturers to help revive our economy, and repealing the job-crushing
medical device tax would be a huge boost to these efforts,” said Mark Leahey, President and CEO of MDMA.
"This bipartisan legislation supports a proud American success story,
and removes a serious barrier to creating jobs and improving patient
care. The small and innovative businesses that comprise the medical
device community are counting on Congress to put an end to this
"Repealing the device tax is critical to saving jobs across the
U.S. Study after study has shown that if this tax is implemented in
January, tens of thousands of good-paying jobs will be at risk,” said Stephen J. Ubl, president and CEO of AdvaMed.
"Congress should take a stand now to protect jobs, encourage
competitiveness and preserve the research and development needed to find
tomorrow’s treatments and cures.”
"MITA members continue to oppose the medical device tax because
it creates strong headwinds against an important sector of the U.S.
economy in difficult economic times,” said Gail Rodriguez, Executive Director of MITA. "Repeal
of the tax is critical to bolstering the economy as it will preserve
thousands of jobs and ensure that manufacturers can continue developing
innovative medical technologies that benefit patients.”
"Allowing this tax to take effect prevents medical device companies from competing on a level playing field,” said Bruce Josten, executive vice president for Government Affairs at the U.S. Chamber of Commerce. "It
will put U.S. medical device companies at a competitive disadvantage to
global competitors. Jobs, economic output, and medical innovations will
be lost. H.R. 436, the ‘Protect Medical Innovation Act,’ would repeal
the medical device tax, preserve Americans' quality of life, protect
American jobs, and defend American innovation.”
"As the world’s
leader in innovative life-saving and life-enhancing treatments and
equipment, medical device manufacturers and their employees are critical
to our nation’s health and prosperity,” said Aric Newhouse, Senior Vice President for Policy and Government Relations for NAM.
"A punitive tax on these manufacturers will only serve to stifle
innovation and cause devastating job losses. With slow economic growth
and weak jobs numbers, it is essential that we repeal this ill-advised
tax on job creators and innovators.”
The $30 billion device tax
would affect many companies that would owe more in taxes than they
generate in profits, as the tax is applied to revenue. This would
result in the elimination of jobs, cuts to research and development
budgets, and roadblocks in the development of new therapies.
To read the letter sent to House leadership, click here.